المؤلفون: Christian U. Blank, Stéphane Dalle, Alexander M.M. Eggermont, Sandrine Marreaud, Matteo S. Carlino, Alfonsus J. M. van den Eertwegh, Stefan Suciu, Nageatte Ibrahim, Rahima Jamal, Paolo A. Ascierto, Alexander C.J. van Akkooi, Michal Kicinski, Piotr Rutkowski, Georgina V. Long, Dirk Schadendorf, Ralf Gutzmer, Shahneen Sandhu, Andrew Haydon, Victoria Atkinson, Susana Puig, Adnan Khattak, Anna Maria Di Giacomo, Clemens Krepler, Mario Mandalà, Rutger H. T. Koornstra, Caroline Robert, Jean-Jacques Grob, Leonel Hernandez-Aya, Paul Lorigan, James Larkin

المساهمون: Medical oncology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology

المصدر: Jama Oncology, 6, 519-527
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial ', JAMA Oncology, vol. 6, no. 4, pp. 519-527 . https://doi.org/10.1001/jamaoncol.2019.5570Test
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical Trial ', JAMA oncology . https://doi.org/10.1001/jamaoncol.2019.5570Test
Jama Oncology, 6, 4, pp. 519-527
JAMA Oncology, 6(4), 519-527. American Medical Association

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Population, Medizin, Pembrolizumab, Placebo, Antibodies, Monoclonal, Humanized, Disease-Free Survival, law.invention, Placebos, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Medicine, Humans, 030212 general & internal medicine, education, Adverse effect, Melanoma, Aged, Neoplasm Staging, Proportional Hazards Models, education.field_of_study, Manchester Cancer Research Centre, business.industry, Proportional hazards model, ResearchInstitutes_Networks_Beacons/mcrc, Hazard ratio, Middle Aged, Ipilimumab, Clinical trial, Oncology, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9b431bc34ae329792ac7bd923376806Test
https://hdl.handle.net/2066/218502Test

المؤلفون: Roland Van Velthoven, Sandrine Marreaud, Peter F.A. Mulders, Christian U. Blank, Sylvie Rottey, Sandra Collette, Johannes V. Van Thienen, Laurence Collette, Thomas Powles, Axel Bex, Lori Wood, Harm H.H.E. Van Melick, Jean Baptiste Lattouf, Igle J. de Jong, John B. A. G. Haanen, John Wagstaff, Bertrand Tombal, Michael A.S. Jewett, M.P. Laguna, Maureen J.B. Aarts

المساهمون: UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Bex, Axel, van Thienen, Johannes V., Blank, Christian U., Haanen, John Netherlands Canc Inst, Amsterdam, Netherlands, Mulders, Peter Catholic Univ Nijmegen, Dept Urol, Nijmegen, Netherlands, Jewett, Michael Princess Margaret Hosp, Dept Urol, Toronto, ON, Canada, Wagstaff, John Cardiff Hosp, Dept Oncol, Cardiff, S Glam, Wales, van Velthoven, Roland Inst Jules Bordet, Dept Urol, Brussels, Belgium, Laguna, Maria del Pilar Istanbul Medipol Univ, Dept Urol, Istanbul, Turkey, Wood, Lori QEII Hlth Sci Ctr, Div Med Oncol, Halifax, NS, Canada, van Melick, Harm H. E. St Antonius Hosp, Dept Urol, Nieuwegein, Netherlands, Aarts, Maureen J. Maastricht Univ, Med Ctr, Dept Oncol, Maastricht, Netherlands, Lattouf, J. B. Univ Montreal, Hosp Ctr, Dept Surg Urol, Quebec City, ON, Canada, Powles, Thomas Royal Free Hosp, Dept Oncol, London, England, Powles, Thomas Queen Mary Univ, London, England, de Jong, Igle Jan Univ Groningen, Univ Med Ctr Groningen, Dept Urol, Groningen, Netherlands, Rottey, Sylvie Ghent Univ Hosp, Dept Med Oncol, Ghent, Belgium, Tombal, Bertrand Clin Univ St Luc, Dept Urol, Brussels, Belgium, Marreaud, Sandrine, Collette, Sandra, Collette, Laurence European Org Res Treatment Canc, Dept Stat, Brussels, Belgium, Collette, Sandra Bristol Myers Squibb, Brussels, Belgium, Uluslararası Tıp Fakültesi, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

المصدر: JAMA oncology, 5 (2
Translational Cancer Research
JAMA oncology, 5(2), 164-170. AMER MEDICAL ASSOC
JAMA oncology, Vol. 5, no. 2, p. 164-170 (2019)
Jama Oncology, 5, 164-170
Jama Oncology, 5, 2, pp. 164-170
JAMA Oncology, 5(2), 164-170. American Medical Association

مصطلحات موضوعية: Male, Cancer Research, Time Factors, medicine.medical_treatment, urologic and male genital diseases, Nephrectomy, law.invention, 0302 clinical medicine, TARGETED THERAPY, Randomized controlled trial, law, Renal cell carcinoma, Clinical endpoint, Sunitinib, 030212 general & internal medicine, Original Investigation, Hazard ratio, Cytoreduction Surgical Procedures, Middle Aged, RADICAL NEPHRECTOMY, CANCER, Kidney Neoplasms, Neoadjuvant Therapy, Progression-Free Survival, Europe, Editorial Commentary, Oncology, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Disease Progression, SURVIVAL, Female, Erratum, medicine.drug, medicine.medical_specialty, Canada, RESECTION, Urology, Antineoplastic Agents, PLANNED NEPHRECTOMY, Drug Administration Schedule, 03 medical and health sciences, MORBIDITY, All institutes and research themes of the Radboud University Medical Center, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], medicine, Humans, Radiology, Nuclear Medicine and imaging, Progression-free survival, Carcinoma, Renal Cell, Protein Kinase Inhibitors, Aged, business.industry, MORTALITY, Généralités, medicine.disease, EFFICACY, Clinical trial, INTERFERON-ALPHA, business

وصف الملف: 1 full-text file(s): application/pdf; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f60e0899118a89e59904c695dfaed4cTest
https://cris.maastrichtuniversity.nl/en/publications/30d5247a-a32b-4965-a17b-ec5771831809Test